Thus, it can be said that TCIPA increases survival of circulating tumor cells due to the presence of integrins and the GP IIb/IIIa receptor on the platelet surface, which via fibrinogen or vWF interact with tumor integrins. This evidence concerns the gene VWF and neoplasm.